secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001213900-26-011844
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CER-1236 first-in-human data show no CRS/ICANS; platelet transfusion independence in index AML patient
--------------------------------------------------------------------------------

- No cytokine release syndrome (CRS) or ICANS observed despite CD28 costimulatory domain and measurable cell expansion.
- Index patient with inv(3) AML achieved platelet transfusion independence for 72 days after multiple CER-1236 doses.
- CER-1236 successfully manufactured for all four enrolled patients; study expanded to include MDS and myelofibrosis.
- TIM-4 ligand target expressed on AML but not healthy bone marrow; no off-tumor cytotoxicity in preclinical safety assays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026011844/0001213900-26-011844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026011844/ea0275412-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-011844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer